NCT06916143View on ClinicalTrials.gov

Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 8, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Healthy Participants
Interventions
DRUG

LY4100511

Administered orally.

DRUG

Rabeprazole

Administered orally.

Trial Locations (2)

33172

RECRUITING

Clinical Pharmacology of Miami, Miami

37920

NOT_YET_RECRUITING

Alliance for Multispecialty Research, LLC, Knoxville

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY